Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NE 3107

Next Previous
Drug Profile

NE 3107

Alternative Names: 17α-ethynyl-5-androstene-3β,7β,17β-triol; 3α-ethynyl-androst-5-ene-3β,7β,17β-triol; HE 3286; NE-3107; Triolex®

Latest Information Update: 14 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hollis-Eden Pharmaceuticals
  • Developer BioVie; Harbor Therapeutics; National Institutes of Health (USA); NeurMedix
  • Class Anti-inflammatories; Antidementias; Antiepileptic drugs; Antifibrotics; Antiglaucomas; Antihyperglycaemics; Antimigraines; Antineoplastics; Antiparkinsonians; Antirheumatics; Hormones; Insulin sensitisers; Nootropics; Obesity therapies; Small molecules
  • Mechanism of Action Interleukin 23 inhibitors; Interleukin 6 inhibitors; Mitogen activated protein kinase 3 inhibitors; Mitogen-activated protein kinase 1 inhibitors; NF-kappa B inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cystic fibrosis

Highest Development Phases

  • Phase III Alzheimer's disease
  • Phase II Parkinson's disease
  • Preclinical Multiple myeloma; Prostate cancer
  • No development reported Drug-induced dyskinesia
  • Discontinued Amyotrophic lateral sclerosis; Cognition disorders; Cystic fibrosis; Epilepsy; Glaucoma; Huntington's disease; Migraine; Myositis; Optic neuritis; Rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus; Ulcerative colitis; Uveitis

Most Recent Events

  • 11 Mar 2024 BioVie plans a phase IIb trial for Parkinson's disease (Monotherapay, Treatment-naive) in the late summer of 2024
  • 01 Mar 2024 Efficacy data from a phase III trial in Alzheimer's disease released by BioVie
  • 01 Mar 2024 Efficacy data from a phase II NM201 trial in Parkinson's disease released by BioVie
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top